Abstract：OBJECTIVE: To investigate the change in dendritic cells (DCs) in children with chronic immune thrombocytopenia (cITP) and the effect of glucocorticoid on DCs in children with cITP. METHODS: Fifteen children with cITP and 20 healthy controls were included in the study. Flow cytometry was used to measure the DC subsets count in the 15 children with cITP before and after glucocorticoid treatment as well as the corresponding values in the 20 healthy controls. The DCs derived from peripheral blood monocytes in children with cITP were cultured in vitro and collected, and their immunophenotypes were determined by flow cytometry. RESULTS: Before glucocorticoid treatment, the children with cITP showed no notable change in the absolute count of myeloid DCs (mDCs) but showed decreased absolute count of plasmacytoid DCs (pDCs) and increased mDC/pDC ratio compared with the healthy controls (P<0.05). After glucocorticoid treatment, the children with cITP demonstrated increased absolute count of pDCs and decreased absolute count of mDCs and mDC/pDC ratio compared with before treatment (P<0.05). Before glucocorticoid treatment, the children with cITP had significantly higher positive rates of HLA-DR, CD80, CD83 and CD86 on peripheral blood DCs than the healthy controls (P<0.01). All the positive rates were significantly decreased after glucocorticoid treatment (P<0.01), so that there was no significant difference from the healthy controls (P>0.05). CONCLUSIONS: Disproportion and functional disturbance of DC subsets is associated with the pathogenesis of cITP in children. Glucocorticoid can strengthen the immunosuppression of DCs in children with cITP, which may contribute to the effectiveness of glucocorticoid as a treatment.
KUANG Wen-Yong,ZHENG Min-Cui,ZHANG Guang-Sen et al. Effect of glucocorticoid on dendritic cells in children with chronic immune thrombocytopenia[J]. CJCP, 2013, 15(2): 91-94.
［2］Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia［J］. Blood, 2010, 115(2): 168-186.
［3］Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura［J］. J Clin Immunol, 2007, 27(6): 557-562.
［5］Mahnke K, Enk AH. Dendritic cells: key cells for the induction of regulatory T cells?［J］. Curr Top Microbiol Immunol, 2005, 293: 133-150.
［6］Watowich SS, Liu YJ. Mechanisms regulating dendritic cell specification and development［J］. Immunol Rev, 2010, 238(1):76-92.
［7］Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2［J］. Science, 2002, 298(5595): 1025-1029.
［8］Reis E, Sousa C. Activation of dendritic cells: translating innate into adaptive immunity［J］. Curr Opin Immunol, 2004, 16(1):21-25.
［9］Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells［J］. J Immunol, 2001, 166(9): 5530-5539.
［10］Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells［J］. J Exp Med, 2002, 195(6): 695-704.
［11］Ouabed A, Hubert FX, Chabannes D, Gautreau L, Heslan M, Josien R. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventionsl spleen dendritic cells［J］. J Immunol, 2008, 180(9): 5862-5870.
［12］Chapuis F, Rosenzwajg M, Yagello M. Differentiation of human dendritic cells from monocytes in vitro［J］. Eur J Immunol, 1997, 27(2):431-441.
［13］Saito A, Yokohama A, Osaki Y, Ogawa Y, Nakahashi H, Toyama K, et al. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia［J］. Eur J Haematol, 2012, 88(4): 340-349.
［14］Zhang XL, Peng J, Sun JZ, Guo CS, Yu Y, Wang ZG, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura［J］. J Thromb Haemost, 2008, 6(1): 158-165.
［16］Rutella S, De Cristofaro R, Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases［J］. Hum Immunol, 2009, 70(5): 360-673.
［17］Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells［J］. Nat Immunol, 2011, 12(9): 870-878.
［18］Xu SQ, Wang CY, Zhu XJ, Dong XY, Shi Y, Peng J, et al. Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia［J］. Ann Hematol, 2012, 91(10): 1623-1631.
